Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

814.39 +2.12 (+0.26%)

Streaming Delayed Price Updated: 1:03 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

58 59 Next >

The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move. ↗

May 29, 2025

Via The Motley Fool

Topics Artificial Intelligence Bankruptcy

10 Health Care Stocks Whale Activity In Today's Session ↗

May 28, 2025

Via Benzinga

3 Value Stocks with Questionable Fundamentals

May 27, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

Does the 23andMe Acquisition Make Regeneron a Buy Now? ↗

May 24, 2025

Via The Motley Fool

Topics Bankruptcy

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years ↗

May 22, 2025

Via Benzinga

Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

May 22, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

3 Cash-Producing Stocks in Hot Water

May 21, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

What's going on in today's session: S&P500 movers ↗

May 20, 2025

Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal ↗

May 19, 2025

Regeneron (REGN) to acquire 23andMe for $256 million, plans to maintain consumer services and uphold privacy policies. Deal expected to close Q3 2025.

Via Benzinga

Regeneron To Buy Assets Of 23andMe For $256M: Retail Says ‘Fantastic’ For Future R&D Efforts ↗

May 19, 2025

Upon closing of the deal, 23andMe will be operated as a wholly owned direct or indirect unit of Regeneron and will continue operations as a personal genomics service.

Via Stocktwits

Topics Artificial Intelligence Bankruptcy

23andMe Finds A Big Biotech Buyer In $256 Million Bankruptcy Auction ↗

May 19, 2025

The acquirer says it will continue 23andMe's consumer genome testing services. It acquired a number of programs, including the biobank.

Via Investor's Business Daily

Topics Bankruptcy

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness

May 19, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale

May 19, 2025

From 23andMe, Inc.

Via GlobeNewswire

3 Stocks That Will Profit From Trump's Drug Price Cut ↗

May 16, 2025

Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.

Via Benzinga

Topics Government

75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition

May 16, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

1 Nasdaq 100 Stock with Exciting Potential and 2 to Think Twice About

May 16, 2025

While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining demand, high costs, or regulatory pressures that...

Via StockStory

Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments

May 15, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025

May 15, 2025

CCOI, AESI, and REGN are near one-year lows but remain favored by analysts; watch these stocks for future growth potential.

Via MarketBeat

Topics Government World Trade

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 ↗

May 14, 2025

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.

Via Benzinga

Beyond The Numbers: 16 Analysts Discuss Regeneron Pharmaceuticals Stock ↗

May 14, 2025

Via Benzinga

Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards? ↗

May 14, 2025

Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April.

Via Benzinga

Topics Stocks

This PVH Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗

May 14, 2025

Via Benzinga

Best Biotech Stocks to Buy in 2025

May 13, 2025

Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.

Via MarketBeat

Topics ETFs Economy Government

REGN Q1 Earnings Call: Pipeline Progress and EYLEA Headwinds Dominate Discussion

May 13, 2025

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was 3%...

Via StockStory

Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots ↗

May 12, 2025

Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space.

Via Benzinga

Topics Artificial Intelligence

Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket ↗

May 12, 2025

What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription...

Via Benzinga

Topics Government

3 of Wall Street’s Favorite Stocks Skating on Thin Ice

May 12, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? ↗

May 11, 2025

The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio?

Via Benzinga

1 Cash-Heavy Stock on Our Buy List and 2 to Ignore

May 09, 2025

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining...

Via StockStory

Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗

May 08, 2025

Let's have a look at the S&P500 stocks with an unusual volume in today's session.

Via Chartmill

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.